Total Payments
$471,176
2024 Payments
$76,651
Companies
18
Transactions
615
Medicare Patients
2,867
Medicare Billing
$926,866
Payment Breakdown by Category
Other$334,260 (70.9%)
Consulting$66,490 (14.1%)
Travel$50,708 (10.8%)
Food & Beverage$19,689 (4.2%)
Education$29.74 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $293,650 | 153 | 62.3% |
| Consulting Fee | $66,490 | 13 | 14.1% |
| Travel and Lodging | $50,708 | 178 | 10.8% |
| Honoraria | $40,610 | 23 | 8.6% |
| Food and Beverage | $19,689 | 246 | 4.2% |
| Education | $29.74 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $177,533 | 221 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $105,992 | 139 | $0 (2024) |
| GlaxoSmithKline, LLC. | $59,483 | 55 | $0 (2024) |
| CALLIDITAS THERAPEUTICS US INC. | $51,040 | 70 | $0 (2024) |
| Travere Therapeutics, Inc. | $41,225 | 72 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $20,439 | 36 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $13,015 | 9 | $0 (2023) |
| La Jolla Pharmaceutical Company | $1,347 | 2 | $0 (2018) |
| GENZYME CORPORATION | $224.96 | 2 | $0 (2018) |
| Ardelyx, Inc. | $139.48 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $76,651 | 95 | Travere Therapeutics, Inc. ($19,875) |
| 2023 | $104,754 | 140 | Aurinia Pharma U.S., Inc. ($27,148) |
| 2022 | $113,841 | 108 | Aurinia Pharma U.S., Inc. ($35,352) |
| 2021 | $65,609 | 88 | Aurinia Pharma U.S., Inc. ($34,026) |
| 2020 | $15,709 | 26 | Otsuka America Pharmaceutical, Inc. ($8,598) |
| 2019 | $38,626 | 68 | Otsuka America Pharmaceutical, Inc. ($37,095) |
| 2018 | $25,935 | 40 | Otsuka America Pharmaceutical, Inc. ($24,489) |
| 2017 | $30,051 | 50 | Otsuka America Pharmaceutical, Inc. ($27,790) |
All Payment Transactions
615 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | — | Consulting Fee | Cash or cash equivalent | $11,826.00 | General |
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | — | Travel and Lodging | Cash or cash equivalent | $120.00 | General |
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | — | Travel and Lodging | Cash or cash equivalent | $52.69 | General |
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | — | Travel and Lodging | Cash or cash equivalent | $41.99 | General |
| 12/12/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/12/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $117.03 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/11/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Travel and Lodging | In-kind items and services | $761.28 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/05/2024 | Travere Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| 12/05/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $184.92 | General |
| 12/05/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $50.00 | General |
| 12/04/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Honoraria | Cash or cash equivalent | $800.00 | General |
| Category: Nephrology | ||||||
| 12/04/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Travel and Lodging | In-kind items and services | $157.25 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/20/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,406.00 | General |
| Category: NEPHROLOGY | ||||||
| 11/17/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: NEPHROLOGY | ||||||
| 11/14/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Travel and Lodging | Cash or cash equivalent | $70.00 | General |
| Category: Nephrology | ||||||
| 11/14/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Travel and Lodging | Cash or cash equivalent | $58.65 | General |
| Category: Nephrology | ||||||
| 11/13/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Travel and Lodging | In-kind items and services | $426.96 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/13/2024 | Otsuka America Pharmaceutical, Inc. | — | Food and Beverage | In-kind items and services | $50.41 | General |
| 11/13/2024 | Otsuka America Pharmaceutical, Inc. | — | Food and Beverage | In-kind items and services | $47.02 | General |
| 11/12/2024 | Otsuka America Pharmaceutical, Inc. | — | Travel and Lodging | In-kind items and services | $1,004.99 | General |
| 11/12/2024 | Otsuka America Pharmaceutical, Inc. | — | Travel and Lodging | In-kind items and services | $266.46 | General |
| 11/12/2024 | Otsuka America Pharmaceutical, Inc. | — | Food and Beverage | In-kind items and services | $144.21 | General |
| 11/06/2024 | Travere Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| 11/06/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $12.00 | General |
| 10/26/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $119.91 | General |
| Category: LUPUS NEPHRITIS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 693 | 1,791 | $1.6M | $197,145 |
| 2022 | 9 | 757 | 2,222 | $2.0M | $243,761 |
| 2021 | 8 | 703 | 2,217 | $2.0M | $252,255 |
| 2020 | 8 | 714 | 2,148 | $1.3M | $233,705 |
Total Patients
2,867
Total Services
8,378
Medicare Billing
$926,866
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 217 | 869 | $590,920 | $88,553 | 15.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 58 | 255 | $459,000 | $46,392 | 10.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 153 | 171 | $225,720 | $25,103 | 11.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 121 | 251 | $215,358 | $20,556 | 9.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 105 | 201 | $94,470 | $13,568 | 14.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 26 | $13,208 | $1,802 | 13.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 16 | 18 | $15,444 | $1,172 | 7.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 240 | 1,232 | $837,760 | $107,869 | 12.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 54 | 333 | $599,400 | $62,116 | 10.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 145 | 178 | $234,960 | $30,087 | 12.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 113 | 203 | $174,174 | $20,871 | 12.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 98 | 162 | $76,140 | $9,822 | 12.9% |
| 99220 | Initial hospital observation care per day, typically 70 minutes | Facility | 2022 | 29 | 32 | $25,824 | $4,900 | 19.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 28 | 28 | $30,380 | $3,831 | 12.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 39 | 42 | $21,336 | $2,868 | 13.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 11 | 12 | $10,680 | $1,397 | 13.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 229 | 1,290 | $877,200 | $115,847 | 13.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 52 | 369 | $664,200 | $72,138 | 10.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 132 | 151 | $199,320 | $26,172 | 13.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 95 | 161 | $138,138 | $17,304 | 12.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 51 | 73 | $37,084 | $5,816 | 15.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 65 | 92 | $43,240 | $5,511 | 12.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 26 | 26 | $28,210 | $3,430 | 12.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 35 | 37 | $31,746 | $3,213 | 10.1% |
| 99220 | Hospital observation care, typically 70 minutes | Facility | 2021 | 18 | 18 | $14,526 | $2,823 | 19.4% |
About Dr. Mohammad Kamgar, M.D
Dr. Mohammad Kamgar, M.D is a Internal Medicine healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/01/2008. The National Provider Identifier (NPI) number assigned to this provider is 1275788440.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mohammad Kamgar, M.D has received a total of $471,176 in payments from pharmaceutical and medical device companies, with $76,651 received in 2024. These payments were reported across 615 transactions from 18 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($293,650).
As a Medicare-enrolled provider, Kamgar has provided services to 2,867 Medicare beneficiaries, totaling 8,378 services with total Medicare billing of $926,866. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Nephrology
- Location Los Angeles, CA
- Active Since 12/01/2008
- Last Updated 11/10/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1275788440
Products in Payments
- JYNARQUE (Drug) $116,889
- LUPKYNIS (Drug) $105,635
- BENLYSTA (Biological) $59,462
- TARPEYO (Drug) $51,040
- SAMSCA (Drug) $44,039
- LOKELMA (Drug) $20,063
- TOLVAPTAN (Drug) $15,561
- GIAPREZA (Drug) $1,347
- FABRAZYME (Drug) $224.96
- XPHOZAH 30 MG (Drug) $139.48
- BRILINTA (Drug) $125.67
- NO PRODUCT DISCUSSED (Drug) $125.00
- FARXIGA (Drug) $124.99
- XARELTO (Drug) $117.76
- Ultomiris (Drug) $111.34
- Renal - PD (Device) $109.22
- Rayaldee (Drug) $101.49
- AURYXIA (Drug) $96.02
- LIVTENCITY (Drug) $45.76
- ACCRUFER (Drug) $31.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Los Angeles
Dr. Thomas Magee, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Dr. Julio Gutierrez, Md, MD
Internal Medicine — Payments: $920,439
Internal Medicine $920,439
Dr. Caroline Piatek, M.d,, M.D,
Internal Medicine — Payments: $468,526
Internal Medicine $468,526
Gottfried Konecny, Md, MD
Internal Medicine — Payments: $399,651
Internal Medicine $399,651
Dr. Elizabeth Volkmann, Md, MD
Internal Medicine — Payments: $397,666
Internal Medicine $397,666
Ivan Ho, Md, MD
Internal Medicine — Payments: $378,999
Internal Medicine $378,999